[go: up one dir, main page]

WO1992005783A1 - Ibuprofen-antihistamine combinations - Google Patents

Ibuprofen-antihistamine combinations Download PDF

Info

Publication number
WO1992005783A1
WO1992005783A1 PCT/US1991/007007 US9107007W WO9205783A1 WO 1992005783 A1 WO1992005783 A1 WO 1992005783A1 US 9107007 W US9107007 W US 9107007W WO 9205783 A1 WO9205783 A1 WO 9205783A1
Authority
WO
WIPO (PCT)
Prior art keywords
antihistamine
ibuprofen
substantially free
composition
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/007007
Other languages
French (fr)
Inventor
Thomas N. Gates
Robert T. Sims
King Chiu Kwan
William Slivka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Merck and Co Inc
Original Assignee
McNeil PPC Inc
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc, Merck and Co Inc filed Critical McNeil PPC Inc
Priority to JP3517917A priority Critical patent/JPH06502166A/en
Publication of WO1992005783A1 publication Critical patent/WO1992005783A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • NSAID NSAID
  • Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID.
  • S-ibuprofen single enantiomer
  • racemic ibuprofen see for example U.S. Patent 4,877,620.
  • Antihistamines useful for the treatment of cold and flu symptoms, may be categorized into conventional and non-sedating antihistamines.
  • the conventional antihistamines exhibit an anticholinergic effect which may be advantageous to the cold/allergy sufferer.
  • the conventional antihistamine may also have an advantage for the subject who wishes to induce drowsiness.
  • Non-sedating antihistamines have significant benefits to the cold/allergy sufferer who needs to maintain alertness.
  • compositions for use in the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism comprising:
  • This invention is also directed to a method of treating pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:
  • This invention is also directed to a method of eliciting an onset enhanced and enhanced response for the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:
  • Substantially free of (R)-ibuprofen should be taken to mean that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10.
  • Substantially free with respect to an antihistamine stereoisomer should be taken to mean that the ratio of that stereoisomer to all other stereoisomers of the antihistamine is at least 90:10.
  • Salts of (S)-ibuprofen include salts with alkali metals, such as sodium or potassium, salts with alkaline earth metals, such as calcium, or salts with other metals such as magnesium, aluminum, iron, zinc, copper, nickel or cobalt.
  • Salts of (S)-ibuprofen further include the amino acid salts, particularly the basic amino acids such as lysine or arginine. Specifically included within the above composition is (S)-ibuprofen- (S)-lysine and (S)-ibuprofen-(R)-lysine.
  • (S)-ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620.
  • Metal salts of ibuprofen may be obtained by contacting a hydroxide, or carbonate with ibuprofen.
  • Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen.
  • compositions of the present invention are useful in the treatment of pain and inflammation and the symptoms such as runny nose, sneezing, sniffles and itchy watering eyes that accompany allergies and colds.
  • (S)-ibuprofen provides a faster onset of pain relief and an enhanced degree of relief compared to racemic ibuprofen. These benefits are increased in an (S)-ibuprofen/antihistamine combination as the antihistamine potentiates the action of (S)-ibuprofen. This has not heretofore been observed because the art has not proposed the combination of the (S)-ibuprofen enantiomer, absent (R)-ibuprofen, with an antihistamine. The presence of the (R)-ibuprofen may blur the potentiated effect.
  • the absence of (R)-ibuprofen provides significant benefits particularly to the subject in the weakened state of a cold or flu condition.
  • the allergic contraindications sometimes associated with ibuprofen administration, and which may be particularly detrimental to the cold/allergy sufferer, are absent or reduced in a composition wherein the (R)-ibuprofen is absent.
  • the subject will no longer need to divert metabolic energy to the inversion of the (R)-enantiomer or the removal of this enantiomer.
  • the absence of inversion reduces or eliminates the formation and incorporation into fatty tissue of hybrid-ibuprofen containing triglycerides .
  • the renal burden and renal toxicities sometimes associated with ibuprofen therapy are reduced or absent in a substantially (R)-ibuprofen free composition.
  • the absence of the inactive substances in the present composition avoids undesirable toxic interactions and clearly avoids the metabolism necessary to remove the nonactive entity.
  • the absence of inactive enantiomers, particularly (R)-ibuprofen provides for significant size and weight advantages in a dosage form, particularly a sustained release dosage form.
  • a sustained release dosage of ibuprofen may have required 800 to 1000 mg
  • the employment of (S)-ibuprofen reduces the weight to 650 to 800 mg, and provides for a more practical size tablet for an ibuprofen/antihistamine combination.
  • EPO publication 348,683 discloses that the combination of a piperidinoalkanol, such as terfenadine, with ibuprofen results in_ a hardened mixture rather than a flowable powder. This was attributed to an incompatability between the substances and the mixture to further processing to form a pharmaceutical dosage having acceptable bioavailability characteristics.
  • the present invention in employing a salt of ibuprofen, particularly the lysine or arginine salt, overcomes the incompatability problem and results in a pharmaceutically acceptable dosage formulation.
  • An effective amount of (S)-ibuprofen, or a salt thereof, for use in an unit dose composition of this invention may range from 50 to 800 mg (S)-ibu- profen.
  • the preferred amount of (S)-ibuprofen is about 100 to 400 mg.
  • the amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.
  • the antihistamine employed herein is selected from the conventional and the non-sedating types.
  • the conventional antihistamines competitively antagonize those pharmacological effects of histamine which are mediated through activation of histamine H 2 -receptor sites on effector cells.
  • the conventional antihistamines also exhibit an anticholinergic (drying) effect.
  • the conventional antihistamine is selected from: chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, hydroxyzine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenhydramine, phenindiamine, pyrilamine, azatadine or diphenhydramine or a pharmaceutically acceptable salt
  • the non-sedating antihistamine is selected from: acrivastine, A ⁇ R-11325, astemizole, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine or terfenadine.
  • any diastereomers and/or enantiomers of each antihistamine are any diastereomers and/or enantiomers of each antihistamine. Where a particular therapeutically active stereoisomer is not commercially available it may be prepared following standard resolution chemistry from the available racemic mixture.
  • the amount of the antihistamine useful in the practice of the present invention may vary from about 1 mg to 100 mg depending on the specific antihistamine.
  • compositions may be administered in the form of tablets, capsules, elixirs, syrups or a suspension.
  • active components may be admixed with a pharmaceutically acceptable diluent such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol and in a liquid composition, ethyl alcohol.
  • Acceptable binders such as PVP, starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes, may also be admixed with the active components.
  • lubricants such as magnesium stearic acid talc, and disintegrators such as starch, methylcellulose, agar, bentonite and guar gum and super disintegrators such as docusate sodium, sodium starch glycollate or cross linked PVP may also be included.
  • disintegrators such as starch, methylcellulose, agar, bentonite and guar gum and super disintegrators such as docusate sodium, sodium starch glycollate or cross linked PVP may also be included.
  • the active components may also be formulated in sustained release formulations. These formulations may be employed in oral, dermal, rectal or vaginal administrations . Such sustained release forms also include layered formulations which provide for distinct release ratio and thus may be more beneficial in allowing for short and long term relief.
  • sustained release forms also include layered formulations which provide for distinct release ratio and thus may be more beneficial in allowing for short and long term relief.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism, said composition comprising: (i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and (ii) an antihistaminically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.

Description

TITLE OF THE INVENTION IBUPROFEN-ANTIHISTAMINE COMBINATIONS
BACKGROUND OF THE INVENTION The non-steroidal anti-inflammatory drugs
(NSAID) have been utilized in the treatment of pain/ inflammation and have been disclosed as useful in the treatment, management and mitigation of cold symptoms and the pain associated therewith. Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID. Recently, it has been found that a faster onset of pain relief and an enhanced analgesic response can be obtained by the utilization of the single enantiomer (S)-ibuprofen in comparison to racemic ibuprofen, (see for example U.S. Patent 4,877,620).
Antihistamines, useful for the treatment of cold and flu symptoms, may be categorized into conventional and non-sedating antihistamines. The conventional antihistamines exhibit an anticholinergic effect which may be advantageous to the cold/allergy sufferer. The conventional antihistamine may also have an advantage for the subject who wishes to induce drowsiness. Non-sedating antihistamines have significant benefits to the cold/allergy sufferer who needs to maintain alertness.
Combinations of ibuprofen with antihistamines have been disclosed; however, despite the fact that the allergy and cold/pain sufferer is in need of quick and enhanced relief there has been no consideration given to the employment of (S)-ibuprofen, and more particularly a lysine or arginine salt thereof, in combination with an antihistamine for the treatment of pain and the relief of allergy and cold symptoms.
DETAILED DESCRIPTION OF THE INVENTION
This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism, said composition comprising:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and
(ii) an antihistaminically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
This invention is also directed to a method of treating pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and
(ii) an antihistaminically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
This invention is also directed to a method of eliciting an onset enhanced and enhanced response for the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and
(ii) an antihistaminically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
Substantially free of (R)-ibuprofen should be taken to mean that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10. Substantially free with respect to an antihistamine stereoisomer should be taken to mean that the ratio of that stereoisomer to all other stereoisomers of the antihistamine is at least 90:10.
Salts of (S)-ibuprofen include salts with alkali metals, such as sodium or potassium, salts with alkaline earth metals, such as calcium, or salts with other metals such as magnesium, aluminum, iron, zinc, copper, nickel or cobalt.
Salts of (S)-ibuprofen further include the amino acid salts, particularly the basic amino acids such as lysine or arginine. Specifically included within the above composition is (S)-ibuprofen- (S)-lysine and (S)-ibuprofen-(R)-lysine.
(S)-ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620. Metal salts of ibuprofen may be obtained by contacting a hydroxide, or carbonate with ibuprofen. Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen.
The pharmaceutical compositions of the present invention are useful in the treatment of pain and inflammation and the symptoms such as runny nose, sneezing, sniffles and itchy watering eyes that accompany allergies and colds.
The utilization of (S)-ibuprofen in an analgesic/antihistamine combination offers significant advantages over the combination of racemic ibuprofen with an antihistamine which has already been shown to have advantages over aspirin/acetaminophen combinations (see for example U.S. Patent 4,871,733).
(S)-ibuprofen provides a faster onset of pain relief and an enhanced degree of relief compared to racemic ibuprofen. These benefits are increased in an (S)-ibuprofen/antihistamine combination as the antihistamine potentiates the action of (S)-ibuprofen. This has not heretofore been observed because the art has not proposed the combination of the (S)-ibuprofen enantiomer, absent (R)-ibuprofen, with an antihistamine. The presence of the (R)-ibuprofen may blur the potentiated effect.
Furthermore, the absence of (R)-ibuprofen provides significant benefits particularly to the subject in the weakened state of a cold or flu condition. The allergic contraindications sometimes associated with ibuprofen administration, and which may be particularly detrimental to the cold/allergy sufferer, are absent or reduced in a composition wherein the (R)-ibuprofen is absent. Furthermore, the subject will no longer need to divert metabolic energy to the inversion of the (R)-enantiomer or the removal of this enantiomer. The absence of inversion reduces or eliminates the formation and incorporation into fatty tissue of hybrid-ibuprofen containing triglycerides . The renal burden and renal toxicities sometimes associated with ibuprofen therapy are reduced or absent in a substantially (R)-ibuprofen free composition.
Where only a single stereoisomer of the antihistamine is active (therapeutically active stereoisomer), the absence of the inactive substances in the present composition avoids undesirable toxic interactions and clearly avoids the metabolism necessary to remove the nonactive entity. The absence of inactive enantiomers, particularly (R)-ibuprofen provides for significant size and weight advantages in a dosage form, particularly a sustained release dosage form. Where a sustained release dosage of ibuprofen may have required 800 to 1000 mg, the employment of (S)-ibuprofen reduces the weight to 650 to 800 mg, and provides for a more practical size tablet for an ibuprofen/antihistamine combination.
EPO publication 348,683 discloses that the combination of a piperidinoalkanol, such as terfenadine, with ibuprofen results in_ a hardened mixture rather than a flowable powder. This was attributed to an incompatability between the substances and the mixture to further processing to form a pharmaceutical dosage having acceptable bioavailability characteristics. The present invention in employing a salt of ibuprofen, particularly the lysine or arginine salt, overcomes the incompatability problem and results in a pharmaceutically acceptable dosage formulation.
An effective amount of (S)-ibuprofen, or a salt thereof, for use in an unit dose composition of this invention may range from 50 to 800 mg (S)-ibu- profen. The preferred amount of (S)-ibuprofen is about 100 to 400 mg. The amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.
The antihistamine employed herein is selected from the conventional and the non-sedating types. The conventional antihistamines competitively antagonize those pharmacological effects of histamine which are mediated through activation of histamine H2-receptor sites on effector cells. The conventional antihistamines also exhibit an anticholinergic (drying) effect. The conventional antihistamine is selected from: chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, hydroxyzine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenhydramine, phenindiamine, pyrilamine, azatadine or diphenhydramine or a pharmaceutically acceptable salt
The non-sedating antihistamine is selected from: acrivastine, AΞR-11325, astemizole, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine or terfenadine.
Included within this invention are any diastereomers and/or enantiomers of each antihistamine. Where a particular therapeutically active stereoisomer is not commercially available it may be prepared following standard resolution chemistry from the available racemic mixture.
The amount of the antihistamine useful in the practice of the present invention may vary from about 1 mg to 100 mg depending on the specific antihistamine.
The present compositions may be administered in the form of tablets, capsules, elixirs, syrups or a suspension. For oral administration the active components may be admixed with a pharmaceutically acceptable diluent such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol and in a liquid composition, ethyl alcohol. Acceptable binders such as PVP, starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes, may also be admixed with the active components. Where necessary lubricants such as magnesium stearic acid talc, and disintegrators such as starch, methylcellulose, agar, bentonite and guar gum and super disintegrators such as docusate sodium, sodium starch glycollate or cross linked PVP may also be included.
The active components may also be formulated in sustained release formulations. These formulations may be employed in oral, dermal, rectal or vaginal administrations . Such sustained release forms also include layered formulations which provide for distinct release ratio and thus may be more beneficial in allowing for short and long term relief. The following examples illustrate the compositions of the present invention and as such are not to be considered as limiting the invention set forth in the claims appended hereto.
EXAMPLE 1
(S)-ibuprofen. Conventional Antihistamine Tablet
(S)-ibuprofen-(S)-lys Dexchlorpheniramine m
PVP
Avicel PH101
Magnesium Stearate
Figure imgf000011_0001
(S)-ibuprofen. Conventional Antihistamine Sustained Release
(S)-ibuprofen 400 mg
Dexchlorpheniramine maleate 10 mg
PVP 30 mg
Avicel PH101 80 mg
Magnesium Stearate 8 mg
Methocel E10MCR 66 mg
Methocel K100MLV 200 mg
EXAMPLE 3
(S)-ibuprofen-(S)-lysine/conventional antihistamine Solution
(S)-ibuprofen-(S)-lysine 342 mg
Dexchlorpheniramine maleate 2 mg q.s . syrup 5 ml EXAMPLE 4
(S)-ibuprofen. Non-Sedating Antihistamine Tablet
(S)-ibuprofen-(S)-lysine 342 mg terfenadine 60 mg
PVP 15 mg
Avicel PH101 40 mg
Magnesium Stearate 4 mg
EXAMPLE 5
- - n tih s a s a n d
Figure imgf000012_0001
(S)-ibuprofen-(S)-lysine 342 mg terfenadine 10 mg q.s . syrup 5 ml

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutical composition for use in the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism and adapted for unit dosage oral administration, said composition comprising:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and
(ii) an antihistiminically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
2. A composition of Claim 1 where the ibuprofen is present as the salt (S)-ibuprofen- (S)-lysine, or (S)-ibuprofen-(R)-lysine.
3. A composition of Claim 1 comprising at least 50 mg of (S)-ibuprofen.
4. A composition of Claim 1 wherein the antihistamine is a conventional antihistamine.
5. A composition of Claim 4 wherein the conventional antihistamine is selected from: chlorpheniramine, brompheniramine, dexchlor¬ pheniramine, dexbrompheniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenhydramine, phenindiamine, pyrilamine, azatadine, diphenhydramine, or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers, or a pharmaceutically acceptable salt.
6. A composition of Claim 4 wherein the conventional antihistamine is selected from chlorpheniramine, brompheniramine, diphenhydramine, or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers, or a pharmaceutically acceptable salt.
7. A composition of Claim 1 wherein the antihistamine is a non-sedating antihistamine.
8. A composition of Claim 7 wherein the non-sedating antihistamine is selected from: acrivastine, AHR-11325, astemizole, azelastine, cetirizine, ebastine, ketotifen, lodoxa ide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine or terfenadine, or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers, or a pharmaceutically acceptable salt.
9. A method of treating pain and inflammation and the relief of allergy and cold symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuρrofen, or a salt thereof, substantially free of (R)-ibuprofen; (ii) an antihistamically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
10.A method of Claim 9 wherein the antihistamine is a conventional antihistamine.
11. A method of Claim 9 wherein the antihistamine is a non-sedating antihistamine.
12. A method of eliciting an onset hastened and enhanced response for the treatment of pain and inflammation and the relief of allergy and cold symptoms in a mammalian, organism in need of such treatment, comprising administering to such organism.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and
(ii) an antihistamically effective amount of at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
13. A method of Claim 12 wherein the antihistamine is a conventional antihistamine.
14. A method of Claim 12 wherein the antihistamine is a non-sedating antihistamine.
15. A method of reducing the side effects associated with the administration of an ibuprofen/antihistamine combination which comprises the aministration of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen, and at least one of the anthistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
16. A method of Claim 15 wherein the antihistamine is a conventional antihistamine.
17. A method of Claim 15 wherein the antihistamine is a non-sedating antihistamine.
18. A method of reducing the size and weight of an ibuprofen/antihistamine combination dosage form which comprises combining (S)-ibuprofen, or salt thereof, substantially free of (R)-ibuprofen and at least one of the antihistamines or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.
19. A method of Claim 18 wherein the antihistamine is a conventional antihistamine.
20. A method of Claim 18 wherein the antihistamine is a non-sedating antihistamine.
PCT/US1991/007007 1990-09-28 1991-09-25 Ibuprofen-antihistamine combinations Ceased WO1992005783A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3517917A JPH06502166A (en) 1990-09-28 1991-09-25 Ibuprofen-antihistamine combination

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58924190A 1990-09-28 1990-09-28
US58924590A 1990-09-28 1990-09-28
US589,245 1990-09-28
US589,241 1990-09-28

Publications (1)

Publication Number Publication Date
WO1992005783A1 true WO1992005783A1 (en) 1992-04-16

Family

ID=27080486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/007007 Ceased WO1992005783A1 (en) 1990-09-28 1991-09-25 Ibuprofen-antihistamine combinations

Country Status (5)

Country Link
EP (1) EP0550668A4 (en)
JP (1) JPH06502166A (en)
AU (1) AU8764191A (en)
CA (1) CA2092566A1 (en)
WO (1) WO1992005783A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014449A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Compositions containing caffeine and s(+)-ibuprofen or s(+)-flurbiprofen or s(+)-ketoprofen
WO1995011677A1 (en) * 1993-10-25 1995-05-04 Merrell Pharmaceuticals Inc. A stable pharmaceutical composition of terfenadine and ibuprofen
WO1995025518A1 (en) * 1994-03-18 1995-09-28 Ciba-Geigy Ag Aqueous solution of levocabastine for ophthalmic use
WO1997004808A1 (en) * 1995-07-28 1997-02-13 The Procter & Gamble Company Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
EP0663819A4 (en) * 1992-09-29 1998-05-27 Merck & Co Inc IBUPROFEN-COFFEINE COMBINATIONS.
WO2009145921A1 (en) * 2008-05-30 2009-12-03 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
EP2240018A4 (en) * 2008-01-04 2012-01-11 Schabar Res Associates Llc METHODS OF MEASURING A PATIENT'S RESPONSE TO THE ADMINISTRATION OF A MEDICAMENT OR ITS COMPOSITIONS
EP2493465A4 (en) * 2009-10-26 2012-09-05 Sephoris Pharmaceuticals Llc TREATMENT OF SUNBURN WITH PAIN AND ANTIHISTAMINES
WO2016154028A1 (en) 2015-03-26 2016-09-29 Iversen Jacqueline M Methods and compositions to inhibit symptoms associated with veisalgia
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
EP4226923A4 (en) * 2020-12-04 2024-08-21 Laboratorios Silanes, S.A. de C.V. PHARMACEUTICAL COMPOSITION CONTAINING AN ANALGESIC AND AN ANTIHISTAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4614638B2 (en) * 2002-06-07 2011-01-19 第一三共株式会社 Analgesic composition
JP2010159299A (en) * 2002-07-04 2010-07-22 Daiichi Sankyo Co Ltd Antipyretic composition comprising loxoprofen and ketotifen
JP4614640B2 (en) * 2002-07-04 2011-01-19 第一三共株式会社 Antipyretic composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4851444A (en) * 1987-07-10 1989-07-25 Analgesic Associates Onset-hastened/enhanced analgesia
US4877620A (en) * 1986-11-14 1989-10-31 MEDICE Chem.- Pharm. Fabrik Putter GmbH & Co. KG Ibuprofen-containing medicament
US4980375A (en) * 1987-07-10 1990-12-25 Sterling Drug Inc. Onset-hastened/enhanced antipyretic response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4877620A (en) * 1986-11-14 1989-10-31 MEDICE Chem.- Pharm. Fabrik Putter GmbH & Co. KG Ibuprofen-containing medicament
US4851444A (en) * 1987-07-10 1989-07-25 Analgesic Associates Onset-hastened/enhanced analgesia
US4980375A (en) * 1987-07-10 1990-12-25 Sterling Drug Inc. Onset-hastened/enhanced antipyretic response

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0663819A4 (en) * 1992-09-29 1998-05-27 Merck & Co Inc IBUPROFEN-COFFEINE COMBINATIONS.
AU672279B2 (en) * 1992-12-21 1996-09-26 Procter & Gamble Company, The Compositions containing caffeine and S(+)-ibuprofen or S(+)-flurbiprofen or S(+)-ketoprofen
WO1994014449A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Compositions containing caffeine and s(+)-ibuprofen or s(+)-flurbiprofen or s(+)-ketoprofen
CN1060040C (en) * 1993-10-25 2001-01-03 默里尔药物公司 A stable pharmaceutical composition of terfenadine and isuprofen
WO1995011677A1 (en) * 1993-10-25 1995-05-04 Merrell Pharmaceuticals Inc. A stable pharmaceutical composition of terfenadine and ibuprofen
WO1995025518A1 (en) * 1994-03-18 1995-09-28 Ciba-Geigy Ag Aqueous solution of levocabastine for ophthalmic use
WO1997004808A1 (en) * 1995-07-28 1997-02-13 The Procter & Gamble Company Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
EP2240018A4 (en) * 2008-01-04 2012-01-11 Schabar Res Associates Llc METHODS OF MEASURING A PATIENT'S RESPONSE TO THE ADMINISTRATION OF A MEDICAMENT OR ITS COMPOSITIONS
US9044465B2 (en) 2008-01-04 2015-06-02 Schabar Research Associates, Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
AU2009204360B2 (en) * 2008-01-04 2014-12-18 Src, Inc. The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound and single dose compositions thereof
WO2009145921A1 (en) * 2008-05-30 2009-12-03 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
WO2009158144A1 (en) * 2008-05-30 2009-12-30 Fairfield Clinical Trials Llc Method and composition for dermatoses
EP2853262A1 (en) * 2009-10-26 2015-04-01 Sephoris Pharmaceuticals, LLC Treatment of sunburn using analgesics and antihistamines
US10751331B2 (en) 2009-10-26 2020-08-25 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
EP2493465A4 (en) * 2009-10-26 2012-09-05 Sephoris Pharmaceuticals Llc TREATMENT OF SUNBURN WITH PAIN AND ANTIHISTAMINES
US8957095B2 (en) 2009-10-26 2015-02-17 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
AU2010315561B2 (en) * 2009-10-26 2016-10-20 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
US9895360B2 (en) 2009-10-26 2018-02-20 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
CN107635549A (en) * 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 Methods and compositions for suppressing symptoms associated with hangovers
WO2016154028A1 (en) 2015-03-26 2016-09-29 Iversen Jacqueline M Methods and compositions to inhibit symptoms associated with veisalgia
AU2016235484B2 (en) * 2015-03-26 2021-02-18 Jacqueline M. Iversen Methods and compositions to inhibit symptoms associated with veisalgia
EP3273952B1 (en) * 2015-03-26 2022-06-15 Sen-Jam Pharmaceutical LLC Combination of naproxen and fexofenadine to inhibit symptoms associated with veisalgia
CN115887456A (en) * 2015-03-26 2023-04-04 杰奎琳·M·艾弗森 Methods and compositions for suppressing symptoms associated with hangovers
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US12048690B2 (en) 2020-07-15 2024-07-30 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US12053457B2 (en) 2020-07-15 2024-08-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
EP4226923A4 (en) * 2020-12-04 2024-08-21 Laboratorios Silanes, S.A. de C.V. PHARMACEUTICAL COMPOSITION CONTAINING AN ANALGESIC AND AN ANTIHISTAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES

Also Published As

Publication number Publication date
JPH06502166A (en) 1994-03-10
AU8764191A (en) 1992-04-28
EP0550668A4 (en) 1993-10-13
CA2092566A1 (en) 1992-03-29
EP0550668A1 (en) 1993-07-14

Similar Documents

Publication Publication Date Title
WO1992005783A1 (en) Ibuprofen-antihistamine combinations
WO1992017177A1 (en) Ibuprofen-antitussive combinations
US4619934A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
RU2182000C2 (en) Ibuprofen dosed form
EP0324007B1 (en) A pharmaceutical composition containing s(+) ibuprofen substantially free of its r(-) antipode
JP2763634B2 (en) Onset enhanced / augmented analgesia
EP0311677B1 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
US5025019A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0630239A1 (en) Antipyretic and analgesic methods and compositions containing optically pure r(-) ketoprofen
WO1995007103A1 (en) Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
WO1994003170A1 (en) Terfenadine metabolites and their optically pure isomers for treating allergic disorders
EP0871440A1 (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
JP2002529407A (en) L-DOPA ethyl ester-containing dispersible composition
US5260337A (en) Ibuprofen-muscle relaxant combinations
AU1989697A (en) Caffeine and clemastine for treating respiratory disorders
WO1999015173A1 (en) Compositions and methods for treating respiratory disorders
JP2012025778A (en) Fenofibrate-containing composition
AU3806393A (en) Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
CA2151912A1 (en) Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
JP2005187328A (en) Antipyretic analgesic composition containing ibuprofen and cold medicine
WO1997004808A1 (en) Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
IE913184A1 (en) Method for treating respiratory disorders
CA1124647A (en) Analgesic potentiation
JPH06500129A (en) nucleoside derivatives
EP0550689A1 (en) Ibuprofen-diuretic combinations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KR LK MC MG MN MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991918783

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2092566

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991918783

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991918783

Country of ref document: EP